Europe Gastrointestinal Therapeutics Market Size & Outlook
Europe gastrointestinal therapeutics market, 2018-2030 (US$M)
Related Markets
Europe gastrointestinal therapeutics market highlights
- The Europe gastrointestinal therapeutics market generated a revenue of USD 11,015.2 million in 2022.
- The market is expected to grow at a CAGR of 2.7% from 2023 to 2030.
- In terms of segment, branded was the largest revenue generating drug type in 2022.
- Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
- Country-wise, Spain is expected to register the highest CAGR from 2023 to 2030.
Europe data book summary
| Market revenue in 2022 | USD 11,015.2 million |
| Market revenue in 2030 | USD 13,638.2 million |
| Growth rate | 2.7% (CAGR from 2022 to 2030) |
| Largest segment | Branded |
| Fastest growing segment | Generics |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Branded, Generics |
| Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
Other key industry trends
- In terms of revenue, Europe region accounted for 29.3% of the global gastrointestinal therapeutics market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 13,118.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gastrointestinal Therapeutics Market Scope
Gastrointestinal Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe gastrointestinal therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 69.08% in 2022. Horizon Databook has segmented the Europe gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the second largest share in the gastrointestinal therapeutics market in 2019. The region is anticipated to experience a steady CAGR over the forecast period, owing to various patent expirations and the subsequent entry of generics in the coming years.
In addition, increasing collaborations between healthcare organizations to enhance awareness and rising availability of varied treatment options can also be attributed to the significant share garnered by the region.
Moreover, regulatory authorities, such as European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA), are consistently working toward ensuring high safety standards for drugs marketed in the region.
Reasons to subscribe to Europe gastrointestinal therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe gastrointestinal therapeutics market databook
-
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe gastrointestinal therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Europe gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe gastrointestinal therapeutics market size, by country, 2018-2030 (US$M)
Europe Gastrointestinal Therapeutics Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
